Accepting applications until August 1
Accepting applications until August 1
Edoardo Botteri, Paula Berstad, Sven Sandin, Elisabete Weiderpass. Acta Oncol. 2021 Jul;60(7):827-834
We investigated this issue in the Swedish Women's Lifestyle and Health Cohort Study. We included 29,930 women. From 1991/92 to 2003, median age changed from 40.0 to 51.7 years, alcohol consumption from 2.5 to 4.7 grams/day, BMI fr... Read More
Pasquale Marino, Mariangela Mininni, Giovanni Deiana, et al. Nutrients. 2024 Mar 11;16(6):800
Cancer has become a serious problem worldwide, as it represents the main cause of death, and its incidence has increased over the years. A potential strategy to counter the growing spread of various forms of cancer is the adoption... Read More
Xiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, et al. Lancet Oncol. 2025 Jan;26(1):27-36
We aimed to evaluate the efficacy of weekly nab-paclitaxel compared with the standard regimen of docetaxel plus carboplatin, both with trastuzumab and pertuzumab, as neoadjuvant therapies for patients with HER2-positive breast can... Read More
Peter Schmid, Javier Cortes, Rebecca Dent, et al. N Engl J Med. 2024 Nov 28;391(21):1981-1991
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-con... Read More
Fatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al. Nat Med. 2025 Feb;31(2):442-448
We conducted a double-blind, placebo-controlled phase 3 study (KEYNOTE-756) in which patients with previously untreated ER+/HER2-grade 3 high-risk invasive breast cancer (T1c-2 (≥2 cm), cN1-2 or T3-4, cN0-2) were randomly assigned... Read More
Sherene Loi, Roberto Salgado, Giuseppe Curigliano, et al. Nat Med. 2025 Feb;31(2):433-441
We conducted a randomized, multicenter, double-blind phase 3 trial to investigate the benefit of adding nivolumab to neoadjuvant chemotherapy in patients with newly diagnosed, high-risk, grade 3 or 2 (ER 1 to ≤10%) ER+/HER2- prima... Read More
Elizabeth A Mittendorf, Zoe June Assaf, Nadia Harbeck, et al. Nat Med. 2025 Jul;31(7):2397-2404
Patients with previously untreated stage II/III TNBC enrolled in 75 academic and community sites in 13 countries were randomized 1:1 to receive neoadjuvant chemotherapy with either peri-operative atezolizumab (n = 165) or preopera... Read More
M Graeser, O Gluz, C Zu Eulenburg, et al. Ann Oncol. 2025 Nov;36(11):1366-1378
A total of 713 patients were analyzed; neoadjuvant chemotherapy (paclitaxel plus pertuzumab plus trastuzumab): n = 149, neoadjuvant chemotherapy-free (pertuzumab plus trastuzumab, trastuzumab-only)/antibody-drug conjugate (ADC, tr... Read More
Toralf Reimer, Thorsten Kuehn, Volkmar Mueller, et al. Eur J Surg Oncol 2025 Nov;51(11):110445
The German Guideline Commission (AGO: Working Group on Gynecologic Cancers) updated its recommendations on the diagnosis and treatment of breast cancer in March 2025. The most important changes include the incorporation of INSEMA... Read More
N Harbeck, S Modi, L Pusztai, et al. Ann Oncol. 2026 Feb;37(2):166-179
DESTINY-Breast11 assessed efficacy and safety of neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) versus dose-dense doxorubicin + cyclophosphamide (ddAC) followed by THP f... Read More
Sibylle Loibl, Yeon Hee Park, Zhiming Shao, et al. N Engl J Med. 2026 Feb 26;394(9):845-857
A total of 1635 patients were randomly assigned (in a 1:1 ratio) to receive T-DXd (818 patients) or T-DM1 (817 patients). Invasive-disease events or deaths were reported in 51 patients (6.2%) in the T-DXd group and 102 patients (1... Read More
Sherko Kuemmel, Peter A Fasching, Peter Schmid, et al. Ann Surg Oncol. 2026 Feb 25
We prospectively evaluated surgical outcomes following neoadjuvant pembrolizumab or placebo added to neoadjuvant chemotherapy among participants with early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 stud... Read More